Does Medicare Advantage Cover Testosterone Enanthate?

How Medicare Advantage Covers Testosterone Enanthate

Medicare Advantage (MA) plans that include Part D prescription drug benefits cover testosterone enanthate as a medically necessary treatment for male hypogonadism. Coverage is not automatic. Every MA plan sets its own formulary, copay structure, and utilization management rules within the framework CMS establishes each year.

Testosterone enanthate is an injectable testosterone ester approved by the FDA for replacement therapy in conditions associated with deficiency or absence of endogenous testosterone. The drug has been available as a generic for decades, which keeps costs low relative to newer formulations like testosterone undecanoate (Aveed) or subcutaneous auto-injectors (Xyosted). Because generics dominate the market, most MA-PD formularies list testosterone enanthate on Tier 2 (preferred generic) or Tier 3 (non-preferred generic), with monthly copays that typically fall between $10 and $45 depending on the specific plan.

CMS does not publish a single national coverage determination for testosterone replacement. Instead, each MA organization files its formulary with CMS and applies its own prior authorization criteria. The practical result: coverage varies by carrier, by region, and by plan year. Checking your specific plan's formulary on Medicare.gov's Plan Finder before filling a prescription is the single most reliable step you can take.

Prior Authorization Criteria Across Major MA Carriers

Prior authorization is the most common barrier to coverage. Almost every Medicare Advantage plan requires it for testosterone enanthate, and denial rates increase sharply when documentation is incomplete.

The typical prior authorization checklist includes a confirmed diagnosis of male hypogonadism (ICD-10 E29.1), two morning serum total testosterone levels drawn before 10:00 AM showing values below 300 ng/dL, documentation that symptoms are present (fatigue, decreased libido, erectile dysfunction, loss of muscle mass), and exclusion of reversible causes such as opioid use or obstructive sleep apnea. The Endocrine Society's 2018 Clinical Practice Guideline recommends confirming hypogonadism with at least two morning measurements using a reliable assay, and most MA plans mirror this standard in their authorization criteria.

Some carriers add extra requirements. UnitedHealthcare Medicare Advantage plans, for example, often require documentation that the prescriber considered and addressed modifiable risk factors before starting testosterone. Humana MA plans may require LH and FSH levels to differentiate primary from secondary hypogonadism. Aetna Medicare plans frequently ask for a PSA and hematocrit at baseline.

A clean prior authorization submission should include the two morning testosterone values with dates and times, the ordering diagnosis, relevant symptom documentation, baseline PSA, baseline hematocrit, and a brief clinical note explaining why replacement therapy is indicated. Submitting all of this upfront reduces the denial-and-resubmit cycle that delays treatment by weeks.

Formulary Tier Placement and What It Means for Your Copay

Where testosterone enanthate lands on a plan's formulary tier directly determines your monthly cost. Generic testosterone enanthate 200 mg/mL (the most commonly prescribed concentration) sits on Tier 2 in the majority of MA-PD plans, which means a copay of $5 to $20 per fill at preferred pharmacies.

Plans that place it on Tier 3 (non-preferred generic) charge $20 to $45. A small number of plans with narrow formularies exclude injectable testosterone entirely and cover only topical formulations, pushing patients toward gels like AndroGel or Testim as first-line therapy.

The cost math is worth understanding. Testosterone enanthate is typically prescribed at 100 to 200 mg every one to two weeks. A 5 mL vial of 200 mg/mL contains 1 to 000 mg total, enough for roughly 5 to 10 weeks of therapy depending on dose. The manufacturer list price hovers around $120 per month, but the actual wholesale acquisition cost for generics is far lower, often under $30 per vial. This gap between list price and generic cost means that even patients in the coverage gap (the "donut hole") face manageable out-of-pocket expense.

For comparison, branded testosterone undecanoate (Aveed) carries a list price exceeding $3,500 per injection and is administered every 10 weeks in a clinical setting. The cost differential between generic testosterone enanthate and branded alternatives is one reason MA formulary committees strongly prefer the generic injectable.

Step Therapy Requirements

Some Medicare Advantage plans require step therapy before approving testosterone enanthate. This means you must try (and fail or show intolerance to) a topical testosterone formulation before the plan will authorize the injectable.

Step therapy logic varies. Plans that require it typically accept a 30- to 90-day trial of a topical gel or solution. Documented failure could mean inadequate testosterone level response (levels remaining below 400 ng/dL on appropriate topical dosing), skin reactions at application sites, or concern about transference risk to household contacts (children, pregnant partners). The FDA's boxed warning on topical testosterone specifically addresses secondary exposure risk in children, and citing this warning in a step therapy exception request strengthens the clinical argument for skipping topicals.

Not all plans impose step therapy. If your plan does and you have a clinical reason to start with injectable testosterone enanthate, your prescriber can file a formulary exception request. The request must include a clinical rationale explaining why the preferred step (topical gel) is inappropriate for you specifically.

What Medicare Advantage Does Not Cover

Medicare Part D plans, including the Part D component of Medicare Advantage, cannot cover testosterone enanthate for weight loss. Period. CMS has historically excluded drugs prescribed for weight management from Part D coverage. The Inflation Reduction Act of 2022 and subsequent CMS guidance opened a narrow exception for anti-obesity medications with an approved cardiovascular indication (specifically semaglutide 2.4 mg following its December 2023 MACE indication from the SELECT trial), but testosterone does not carry an obesity or cardiovascular risk reduction indication.

The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg, leading to its expanded FDA indication. Testosterone enanthate has no comparable cardiovascular outcomes trial supporting an obesity or CV indication. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, confirmed that testosterone replacement in men with hypogonadism and cardiovascular risk did not increase the incidence of major adverse cardiac events, but "non-inferiority on CV safety" is not the same as a positive CV outcomes indication.

If a provider submits a prior authorization for testosterone enanthate with a primary diagnosis of obesity (E66.x) rather than hypogonadism (E29.1), the claim will be denied. This is not a gray area.

Coverage also does not extend to testosterone prescribed for age-related decline without documented hypogonadism. The Endocrine Society guideline explicitly recommends against diagnosing testosterone deficiency in men who do not have consistent symptoms and unequivocally low morning testosterone, and MA plans follow this standard.

The T-Trials: The Evidence Base Plans Rely On

When MA medical directors evaluate testosterone coverage policies, the Testosterone Trials (TTrials) are the evidence anchor. This coordinated set of seven placebo-controlled trials enrolled 790 men aged 65 years or older with serum testosterone below 275 ng/dL and symptoms of hypogonadism.

Published in the New England Journal of Medicine in 2016, the Sexual Function Trial showed that testosterone gel (which achieves comparable serum levels to injectable enanthate) significantly improved sexual desire, erectile function, and sexual activity compared to placebo over 12 months. The Physical Function Trial showed a modest improvement in walking distance (6-minute walk test). The Vitality Trial did not demonstrate a statistically significant improvement in fatigue using its primary endpoint, although secondary fatigue measures trended positive.

Dr. Peter Snyder, the principal investigator of the TTrials, stated in the accompanying editorial: "Testosterone treatment increased serum testosterone levels to the mid-normal range and improved sexual function, walking distance, and, to a lesser degree, mood."

These trials form the clinical backbone for MA coverage policies. Plans cover testosterone when the prescribing pattern mirrors the TTrials population: older men with confirmed low testosterone and corresponding symptoms. Prescribing outside this evidence base (young men, normal testosterone levels, performance enhancement) will not meet prior authorization criteria.

How to Appeal a Medicare Advantage Denial

A denied prior authorization is not the end. Medicare Advantage plans are required by federal law to provide a structured appeal process with defined timelines.

The first step is a plan-level redetermination. You or your prescriber must file this within 60 days of the denial notice. Include any additional clinical documentation that addresses the specific reason for denial. If the denial cited missing lab work, submit the labs. If it cited step therapy, document the prior topical trial or explain the clinical exception. Plans must decide standard redeterminations within 7 calendar days (72 hours for expedited requests involving urgent clinical need).

If the plan upholds the denial, the next level is an independent review by a CMS-contracted Independent Review Entity (IRE). For Medicare Advantage Part D drug denials, MAXIMUS Federal Services conducts this review. The IRE must issue a decision within 7 calendar days. MAXIMUS reviewers are physicians who evaluate the clinical evidence independently of the plan's medical directors.

Beyond the IRE, further appeal levels include an Administrative Law Judge (ALJ) hearing (for amounts meeting the threshold, currently $190 for 2026), the Medicare Appeals Council, and federal district court. In practice, most testosterone enanthate denials that reach the IRE with complete documentation are resolved there.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's testosterone guideline, has noted: "When prior authorizations for testosterone are denied, it is almost always because the documentation submitted did not meet the plan's evidentiary standard, not because the patient was ineligible."

Filing a timely appeal with complete documentation is the single most effective action. The denial letter will specify exactly what was missing or insufficient. Address those points directly.

Injectable Testosterone Enanthate vs. Other Covered Formulations

Medicare Advantage formularies typically cover multiple testosterone formulations, but cost and tier placement differ significantly.

Testosterone enanthate and testosterone cypionate are both generic injectables with similar pharmacokinetics, and most plans cover both on the same tier. Clinically, they are interchangeable. Testosterone cypionate has a slightly longer half-life (approximately 8 days vs. 4.5 days for enanthate), but dosing intervals are similar in practice.

Topical testosterone gels (generic AndroGel 1%, generic Testim) usually sit on Tier 2 as well, but monthly costs can be higher because gel formulations are more expensive to manufacture. Branded topicals like AndroGel 1.62% or Natesto nasal gel are typically Tier 4 (non-preferred brand) or Tier 5 (specialty), with copays of $50 to $150 or more.

Testosterone undecanoate (Aveed), an injectable administered every 10 weeks in a healthcare setting, is almost always Tier 5 (specialty) with the highest cost-sharing. Some MA plans exclude it entirely or require failure of self-administered injectables first.

For patients and prescribers focused on minimizing out-of-pocket cost under Medicare Advantage, generic testosterone enanthate or cypionate remains the most cost-effective option by a wide margin.

Tips for Getting Coverage Approved on the First Attempt

Efficient prior authorization starts before the prescription is written. Confirm the diagnosis with two documented morning testosterone levels below 300 ng/dL drawn before 10:00 AM, with dates recorded. Include baseline PSA and hematocrit in the submission. Use ICD-10 code E29.1 (testicular hypofunction) as the primary diagnosis. If your plan requires step therapy, document any prior topical testosterone use, including dates, doses, and reason for discontinuation. Have your prescriber write a brief clinical note (three to four sentences) connecting symptoms to laboratory findings and explaining why testosterone replacement is medically necessary.

Plans process cleaner submissions faster. A complete initial submission with labs, diagnosis, and clinical rationale is approved in 24 to 72 hours on most MA plans. Incomplete submissions trigger additional information requests that delay authorization by 7 to 14 days.